This HTML5 document contains 103 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1093/ANNONC/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q83630735
rdf:type
wikibase:Item
schema:description
artículu científicu espublizáu en marzu de 2012 2012 թվականի մարտի 12-ին հրատարակված գիտական հոդված scientific article published on 12 March 2012 wetenschappelijk artikel article scientifique publié en 2012 наукова стаття, опублікована в березні 2012
p:P577
wds:Q83630735-BE44A398-0A8B-4DFB-9142-D70833CA01AA
wdt:P577
2012-03-12T00:00:00Z
p:P2093
wds:Q83630735-1CAF38E5-6470-4059-A427-95D7B94B39FB wds:Q83630735-21399EDE-2D95-47BC-AC90-FF75EAED4F2D wds:Q83630735-115465E8-080E-435E-A889-E093DF859591 wds:Q83630735-39299E11-E1E2-4DEB-8FE1-AF95C5AE055B wds:Q83630735-40735082-4F0C-48D7-93F2-B2A280393DEF wds:Q83630735-3875C61B-47E6-41D3-9CE8-6DD21C9BACE9 wds:Q83630735-2CD1DCDD-7A6E-48AC-B6E9-A36DEE867532 wds:Q83630735-33BE83B6-1056-403E-A984-4DC05AE8805E wds:Q83630735-854541C0-0A5A-4F73-AB43-26E41B246316 wds:Q83630735-71651465-A57E-4105-8F99-2CB3E2B439A8 wds:Q83630735-7FF22AE6-03DB-442A-BFF6-B0818F489E6D wds:Q83630735-6FA48E8B-FCDF-4DFC-817C-E99A223FB789 wds:Q83630735-5B7D526B-61AA-42F8-BBDE-98B2FC0015FB wds:Q83630735-643DF26D-E265-43B6-9530-1FF2D6AAC548 wds:Q83630735-9FA51610-A0B5-4430-96E2-BF0FFCD76719 wds:Q83630735-8EC8EC4C-CF44-4B43-AACD-0554E9CB357D wds:Q83630735-9624AA5E-C18C-48B1-81CE-7C6A3CC4F2B5 wds:Q83630735-89746789-E5C9-45E4-B3BA-705E32AFD1AE wds:Q83630735-87CE7679-CF8A-48F1-A4D3-CBFC0F84FF4A wds:Q83630735-88184018-B824-4E3E-9E39-76BEEDA2716D wds:Q83630735-A8B6569D-E2CA-4B5C-B186-039E8BBE5F66 wds:Q83630735-EB7F0F90-744C-4A17-951D-D6CAEA80C23A wds:Q83630735-DFA9C2A1-AEB3-4535-9378-3196F5D215B5 wds:Q83630735-DDF28779-35FA-4C52-986C-2A97802FDA72
wdt:P2093
V Tinessa E De Maio G Buonfanti A de Matteis M D'Aiuto F Nuzzo R D'Aniello M Di Bonito E Rossi G Esposito G Landi P Giordano S Signoriello C Gallo A Bartiromo V Labonia F Perrone P Maiolino C Pacilio M C Piccirillo G De Feo F Di Rella G Colantuoni A Gravina
rdfs:label
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
skos:prefLabel
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
schema:name
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
p:P50
wds:Q83630735-B2FB60DF-B0E7-433B-BC7C-E448C9DF25C1 wds:Q83630735-B6C134B9-DE89-40C5-9D0D-30411AEC636D wds:Q83630735-AD7A58F2-A8CE-4C5D-B2D6-DB4A02F87F79 wds:Q83630735-A6D4E1B5-B373-47D1-8478-8C0FED5C3169 wds:Q83630735-08A5C4F8-7B6A-47D3-8587-8F20D7505A1B wds:Q83630735-8B17FC81-B8D4-496B-8B94-FB9E53810F06 wds:Q83630735-F1236584-B9C7-44E8-9293-1E83743F56FF
wdt:P50
wd:Q37828894 wd:Q57052172 wd:Q57081048 wd:Q72031220 wd:Q37828902 wd:Q56380768 wd:Q37828910
p:P1476
wds:Q83630735-E9ECA7DE-DB76-4A39-8AF0-A2A0AF4C471B
wdt:P1476
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study
p:P304
wds:Q83630735-836A39DA-8935-43C5-A3D1-782FBE19B560
wdt:P304
2027-2033
p:P31
wds:Q83630735-F10C85C7-29DB-4F4D-A4B8-9ED865DC4B76
wdt:P31
wd:Q13442814
p:P921
wds:Q83630735-70554E36-667C-4A5F-9A62-B3C311147BE8 wds:Q83630735-354C544B-EF28-4755-9E8E-64B78A213D36 wds:Q83630735-DBD04024-8B20-4D47-AF8E-8C7E7522A435 wds:Q83630735-ABB61DD0-1E3C-410C-ACD6-C6BF5D9E7D59
wdt:P921
wd:Q218507 wd:Q412178 wd:Q128581 wd:Q194974
p:P698
wds:Q83630735-AAB1C808-A542-4980-A705-BAFCF31253DC
wdtn:P698
n12:22412041
wdt:P698
22412041
p:P1433
wds:Q83630735-54315161-F812-4A33-BB80-034DA3F4A82D
wdt:P1433
wd:Q326122
p:P433
wds:Q83630735-C3A72C53-F795-4284-9D9E-698F5424BF27
p:P478
wds:Q83630735-18ECC519-9212-46C3-A6DF-DDF043FCA543
wdt:P433
8
wdt:P478
23
p:P356
wds:Q83630735-4AD8163B-BB6C-4139-9045-515FA97B10A4
wdtn:P356
n10:MDR600
wdt:P356
10.1093/ANNONC/MDR600